This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Romosozumab

Amgen, Inc.

Drug Names(s): AMG 785, CDP7851, sclerostin Ab, anti-sclerostin

Description: AMG 785 is an anti-sclerostin antibody. Sclerostin is a secreted protein made by bone cells and is an inhibitor of bone formation.

Deal Structure: Celltech and Amgen
In May 2002, Celltech Group announced an agreement with Amgen for the research, development and global commercialization of novel treatments for osteoporosis, utilizing Celltech's proprietary antibody fragment technology.

Under the terms of the agreement, Amgen receives exclusive worldwide rights to develop and market treatments targeting the Sclerostin protein. Celltech will be responsible for the identification and engineering of high affinity PEGylated antibody fragments against the Sclerostin protein, using its proprietary antibody fragment technology. Celltech will pay a proportion of all development costs up until the end of Phase II.

Amgen will be responsible for worldwide development. At the start of Phase III, Celltech has the option to co-invest in late stage development and will then lead promotional activities in the European Union. Amgen will lead promotion in North America and Japan.

Alternatively, at Celltech's option, Amgen will...See full deal structure in Biomedtracker

Partners: UCB SA Astellas Pharma, Inc.


Romosozumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug